Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Treatable Hormonal Condition Sometimes Overlooked In Infertility Patients
A condition known as congenital adrenal hyperplasia, or CAH, is easily treatable but frequently overlooked or misdiagnosed, leading to infertility and other "perplexing symptoms," the New York Times reports. CAH is a hormone deficiency that leads to excess production of androgens, which can hinder ovulation in women and cause low sperm count in men. It also can cause short stature, body odor, acne, irregular menstruation and excessive hair growth. The condition can be diagnosed through a blood test and treated with small doses of the steroid dexamethasone, which can reverse symptoms in three months to two-and-one-half years.According to Maria New, a leading authority on CAH and a professor of pediatrics and human genetics at Mount Sinai School of Medicine, the disease occurs in one in every 100 people in the general population. It is more common among certain ethnic groups, occurring in one in 27 Ashkenazi Jews and one in 40 Hispanics. Not everyone with the condition has symptoms or needs to be treated. The most severe form of the disease, classic CAH, can result in ambiguous genitalia in girls, while the milder nonclassical form sometimes produce no symptoms, the Times reports.Many fertility clinics do not test for the disease or only test after attempting other treatments. Some obstetricians are unaware of CAH and its effect on fertility, according to Zev Rosenwaks, director of the Center for Reproductive Medicine at New York Presbyterian-Weill Cornell hospital. CAH also can be confused with polycystic ovarian syndrome -- which has some similar symptoms -- or early puberty in younger patients (Tarkan, New York Times, 7/7).
new payday loan lenders
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherapy In Animal Models
Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte. The report was published online in the early edition (June 29) of the Proceedings of the National Academy of Science (US). The print version will appear July 14.
News of the day
New Snapshots Show States Vary Widely In Providing Quality Health Care, USA
The Agency for Healthcare Research and Quality"s annual release of state-by-state quality data continues to give states mixed reviews for the quality of care they provide. As in previous years, AHRQ"s 2008 State Snapshots show that no state does well or poorly on all quality measures.
Mental Health

InDex Pharmaceuticals AB Engages PharmaVentures To Facilitate The Licensing Of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early

PharmaVentures Ltd, announced that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures" transactions experience in the healthcare and investment business sectors. Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials. Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program. Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors." A leading results driven organisation, PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company"s core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports. InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis. PharmaVentures


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009